Mathieu Charvériat

About Mathieu Charvériat

Mathieu Charvériat is a leading figure in the French biopharmaceutical sector, best known for his role at THX Pharma, formerly Theranexus. He serves as Chairman and Chief Executive Officer, and is also a co-founder of the company. In that capacity, he combines scientific credibility, strategic leadership, and operational responsibility. THX Pharma, based in Lyon, focuses on developing innovative drug candidates for central nervous system disorders and rare neurological diseases. His background is strongly rooted in science and academic excellence. THX Pharma states that he holds degrees from École Polytechnique and Mines ParisTech, as well as a PhD in neurosciences and cell biology from Université Pierre et Marie Curie. He also completed the HEC Challenge + entrepreneur program, which fits a profile that blends technical rigor, innovation, and entrepreneurial thinking. Before co-founding THX Pharma in March 2013 with Franck Mouthon, he joined the neuroscience research laboratory of the French Alternative Energies and Atomic Energy Commission (CEA) in 2009. There, he worked on prion diseases and non-neuronal cells, alongside research that led to multiple publications and patents related to the modulation of drugs targeting neurons. That research foundation directly shaped the creation and early strategy of the company. As a company leader, Charvériat has helped guide THX Pharma through its development as a listed biotech company and through the advancement of its clinical pipeline. Recent materials show him presenting the company’s strategic direction, including partnership initiatives such as the agreement with Biocodex, and communicating on the group’s positioning, business model, and clinical progress. Overall, his profile reflects a rare combination of research depth, translational pharmacology experience, and founder-led corporate governance. In a demanding biotech environment, Mathieu Charvériat stands out for connecting laboratory innovation with industrial execution and strategic partnerships, aiming to create value around therapies with significant unmet medical need.